BioCentury
ARTICLE | Company News

Soligenix, NIH other news

September 30, 2013 7:00 AM UTC

NIH's National Institute of Allergy and Infectious Diseases (NIAID) awarded Soligenix a contract worth up to $6.4 million to support preclinical development of OrbeShield as a medical countermeasure to treat gastrointestinal acute radiation syndrome (GI ARS). The contract includes a one-year base period, with options to extend the contract an additional year each. The oral formulation of beclomethasone dipropionate (BDP) is in preclinical development for GI ARS and has Orphan Drug and Fast Track designations to prevent death following a potentially lethal dose of total body irradiation during or after a radiation disaster. Soligenix plans to conduct a Phase I/II trial of the product in healthy adolescent and young adult volunteers following the completion of an ongoing preclinical canine study, from which data are expected in 1H14. ...